GGrantIndex
← Leaderboards

Cesar M Castro

Massachusetts General Hospital

$5,964,176
Attributed
$13,395,523
Total exposure
7
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4.4M · FY201825
$5M$3.8M$2.5M$1.3M$0
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$20,106,479 · 8

By mechanism

U01$7,867,241 · 3
P50$7,009,447 · 3
R01$5,229,791 · 2

Top collaborators

Most similar at Massachusetts General Hospital

Same institution · by research overlap

Others in their field

Other Emerging Leaders on “Diagnostic

Research focus

DiagnosticSamplingLaboratoriesMultidisciplinaryInnovationPerformanceMalignant NeoplasmsNucleic AcidsResourcesMonitorCancer PatientTechnologyMassachusettsPathologyWomanGeneral HospitalsMalignant Neoplasm Of OvaryHospitalsScreeningExtracellular VesiclesMolecularLiquid BiopsyProteinsMessenger Rna

Grant awards (24)

Empowering cancer detection and monitoring with CampEx - CRISPR-accelerated molecular profiling of Extracellular vesicles$2,855,619
R01 · FY2025 · CA
Expanding early cancer detection with high throughput OCEANA - Ovarian Cancer Exosome Analysis with Nanoplasmonic Array$941,221
U01 · FY2025 · CA
Composing CODAs to cervical cancer screening through an integrated CRISPR and fluorescent nucleic acid approach$269,601
U01 · FY2025 · CA · contact PI
Composing CODAs to cervical cancer screening through an integrated CRISPR and fluorescent nucleic acid approach$126,580
U01 · FY2025 · CA · contact PI
Composing CODAs to cervical cancer screening through an integrated CRISPR and fluorescent nucleic acid approach$124,429
U01 · FY2025 · CA · contact PI
Dana Farber/Harvard Cancer Center Ovarian Cancer SPORE grant$2,309,363
P50 · FY2024 · CA
Expanding early cancer detection with high throughput OCEANA - Ovarian Cancer Exosome Analysis with Nanoplasmonic Array$894,161
U01 · FY2024 · CA
High throughput nanoplasmonic exosome testing (NEXT) of immunotherapies in bladder cancer$629,224
R01 · FY2024 · CA · contact PI
Composing CODAs to cervical cancer screening through an integrated CRISPR and fluorescent nucleic acid approach$527,535
U01 · FY2024 · CA · contact PI
Career Enhancement Program (CEP)$80,540
P50 · FY2024 · CA · contact PI
Dana Farber/Harvard Cancer Center Ovarian Cancer SPORE grant$2,245,572
P50 · FY2023 · CA
Expanding early cancer detection with high throughput OCEANA - Ovarian Cancer Exosome Analysis with Nanoplasmonic Array$877,641
U01 · FY2023 · CA
Composing CODAs to cervical cancer screening through an integrated CRISPR and fluorescent nucleic acid approach$574,748
U01 · FY2023 · CA · contact PI
High throughput nanoplasmonic exosome testing (NEXT) of immunotherapies in bladder cancer$433,516
R01 · FY2023 · CA · contact PI
Career Enhancement Program (CEP)$131,004
P50 · FY2023 · CA · contact PI
Dana Farber/Harvard Cancer Center Ovarian Cancer SPORE grant$2,156,021
P50 · FY2022 · CA
High throughput nanoplasmonic exosome testing (NEXT) of immunotherapies in bladder cancer$649,094
R01 · FY2022 · CA · contact PI
Early Detection through Novel OCEAN Technology - Ovarian Cancer Exosomal Analysis with Nanoplasmonics$573,531
U01 · FY2022 · CA
Career Enhancement Program (CEP)$86,947
P50 · FY2022 · CA · contact PI
Early Detection through Novel OCEAN Technology - Ovarian Cancer Exosomal Analysis with Nanoplasmonics$746,693
U01 · FY2021 · CA
High throughput nanoplasmonic exosome testing (NEXT) of immunotherapies in bladder cancer$662,338
R01 · FY2021 · CA · contact PI
Early Detection through Novel OCEAN Technology - Ovarian Cancer Exosomal Analysis with Nanoplasmonics$746,693
U01 · FY2020 · CA
Early Detection through Novel OCEAN Technology - Ovarian Cancer Exosomal Analysis with Nanoplasmonics$705,145
U01 · FY2019 · CA
Early Detection through Novel OCEAN Technology - Ovarian Cancer Exosomal Analysis with Nanoplasmonics$759,263
U01 · FY2018 · CA